Eli Lilly’s existing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform remains limited to internal R&D use and runs through its October 7, 2026 endpoint. The original October 2024 deal positioned any commercial license as a potential follow-on step only after successful testing of the ultrasonic spray-drying formulation on Lilly’s peptide assets, with no public confirmation of positive results or active negotiations to date. Lilly has simultaneously advanced alternative long-acting delivery technologies, such as its Camurus FluidCrystal partnership, reducing urgency around SmartDepot. With roughly four months remaining and typical timelines for due diligence, term-sheet negotiation, and board approvals in biotech platform deals, traders assign roughly 75% probability to no commercial licensing announcement by the resolution date.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado$10,127 Vol.
$10,127 Vol.
7 oct 2026
$10,127 Vol.
$10,127 Vol.
7 oct 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform remains limited to internal R&D use and runs through its October 7, 2026 endpoint. The original October 2024 deal positioned any commercial license as a potential follow-on step only after successful testing of the ultrasonic spray-drying formulation on Lilly’s peptide assets, with no public confirmation of positive results or active negotiations to date. Lilly has simultaneously advanced alternative long-acting delivery technologies, such as its Camurus FluidCrystal partnership, reducing urgency around SmartDepot. With roughly four months remaining and typical timelines for due diligence, term-sheet negotiation, and board approvals in biotech platform deals, traders assign roughly 75% probability to no commercial licensing announcement by the resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado abierto: May 5, 2026, 8:02 PM ET
Volumen
$10,127Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform remains limited to internal R&D use and runs through its October 7, 2026 endpoint. The original October 2024 deal positioned any commercial license as a potential follow-on step only after successful testing of the ultrasonic spray-drying formulation on Lilly’s peptide assets, with no public confirmation of positive results or active negotiations to date. Lilly has simultaneously advanced alternative long-acting delivery technologies, such as its Camurus FluidCrystal partnership, reducing urgency around SmartDepot. With roughly four months remaining and typical timelines for due diligence, term-sheet negotiation, and board approvals in biotech platform deals, traders assign roughly 75% probability to no commercial licensing announcement by the resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$10,127Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s existing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform remains limited to internal R&D use and runs through its October 7, 2026 endpoint. The original October 2024 deal positioned any commercial license as a potential follow-on step only after successful testing of the ultrasonic spray-drying formulation on Lilly’s peptide assets, with no public confirmation of positive results or active negotiations to date. Lilly has simultaneously advanced alternative long-acting delivery technologies, such as its Camurus FluidCrystal partnership, reducing urgency around SmartDepot. With roughly four months remaining and typical timelines for due diligence, term-sheet negotiation, and board approvals in biotech platform deals, traders assign roughly 75% probability to no commercial licensing announcement by the resolution date.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes